Adaptive Biotechnologies
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $71,553 | $70,874 | $71,681 | $93,973 |
Gross Profit | 50,965 | 52,166 | 53,457 | 75,816 |
EBITDA | -12,075 | -14,379 | -6,430 | 16,922 |
EBIT | -15,770 | -18,216 | -10,625 | 12,517 |
Net Income | -39,788 | -20,033 | -13,579 | 9,546 |
Net Change In Cash | 71,553 | 70,874 | 71,681 | 93,973 |
Free Cash Flow | -7,584 | -10,333 | 1,419 | -7,536 |
Cash | 169,873 | 77,581 | 70,495 | 55,034 |
Basic Shares | 157,700 | 155,521 | 153,127 | 163,162 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $276,976 | $178,957 | $170,276 | $185,308 |
Gross Profit | 205,617 | 106,877 | 94,723 | 127,399 |
EBITDA | -29,846 | -128,759 | -189,273 | -175,210 |
EBIT | -47,679 | -148,015 | -211,504 | -196,130 |
Net Income | -59,499 | -159,492 | -225,250 | -200,191 |
Net Change In Cash | 276,976 | 178,957 | 170,276 | 185,308 |
Cost of Revenue | -48,775 | |||
Free Cash Flow | -48,945 | -98,876 | -167,021 | -200,294 |
Cash | 70,495 | 47,920 | 65,064 | 90,030 |
Basic Shares | 151,721 | 147,102 | 144,383 | 142,515 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.10 |
2026-03-31 | -$0.13 |
2025-12-31 | -$0.09 |
2025-09-30 | -$0.15 |